# Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

> **NCT03020004** · PHASE2 · COMPLETED · sponsor: **Ascletis Pharmaceuticals Co., Ltd.** · enrollment: 70 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Danoprevir
- **DRUG:** Ritonavir
- **DRUG:** peginterferon alfa-2a
- **DRUG:** Ribavirin (RBV)

## Key facts

- **NCT ID:** NCT03020004
- **Lead sponsor:** Ascletis Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-11
- **Final completion:** 2017-02
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03020004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03020004, "Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03020004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*